Pharmaceutical giant G-S-K has lifted its profits and sales growth targets for the year.

Based in Brentford for the last 20 years, the firm told shareholders that sales grew by 13% to £7.9 billion in the second quarter of 2024.

It’s put the performance down to a boost from cancer and HIV treatments.